Insider Selling: Thermo Fisher Scientific (NYSE:TMO) CEO Sells $6,292,700.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Trading Down 0.5%

TMO opened at $630.66 on Friday. The stock has a market capitalization of $233.18 billion, a price-to-earnings ratio of 33.92, a P/E/G ratio of 2.58 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The company has a 50-day simple moving average of $555.52 and a 200 day simple moving average of $511.31.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the firm earned $4.28 EPS. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a report on Wednesday, August 5th. Royal Bank Of Canada lifted their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Finally, Piper Sandler upped their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $619.41.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently bought and sold shares of the company. Tsfg LLC increased its stake in shares of Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after buying an additional 19 shares during the period. Elyxium Wealth LLC grew its holdings in Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after acquiring an additional 20 shares during the last quarter. Renasant Bank increased its position in Thermo Fisher Scientific by 1.0% in the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after acquiring an additional 20 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its stake in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company’s analytical-instrument portfolio and strengthen its position in advanced materials research. Thermo Fisher Scientific Introduces the EMPAD G2 Electron Detector
• Positive Sentiment: A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company’s exposure to emerging research and laboratory markets. Can Isora Unlock a New Growth Edge?
• Neutral Sentiment: Thermo Fisher’s latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock’s elevated valuation.
• Neutral Sentiment: Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation.
• Negative Sentiment: CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.